0
0
6/14/21 at 8:20am
Organization
News-Medical.Net
43 words
0
Comments
Enterprise Therapeutics Ltd today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD001.
You are the first to view
https://www.news-medical.net/news/20210614/Enterprise-Therapeutics-doses-first-subjects-in-Phase-I-trial-for-novel-cystic-fibrosis-therapy-ETD001.aspx
Create an account
or login to join the discussion